Akron Children's Hospital > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies

PBTC 039 - Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery

Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma

Description:

For complete information, please visit the study on clinicaltrials.gov

This study is being done in collaboration with Cincinnati Children's Hospital.

Study Status:

Closed

Full IRB Study Title:

PBTC-039: Phase II Study of Peginterferon alfa-2b (PEGIntron) for Pediatric Patients with Un-resectable or Recurrent Craniopharyngioma - Cincinnati

IRB Study ID:

141110

If you are interested in this study or have questions about your child's eligibility, please contact:

Rebecca D. Considine Research Institute, 330-543-3193 or email research@akronchildrens.org

Lead Investigator

Steven Kuerbitz, MD

Director, Divisional Research, Stem Cell Transplantation & Shannon E. Wilkes Targeted Therapy Program; The Jeffrey A. Barbour Chair for Pediatric Hematology Oncology Research and Healing; Pediatric Hematologist-Oncologist
Showers Family Center for Childhood Cancer and Blood DisordersPediatric Stem Cell Transplant Program

Search our Site

Need Help?

Operator

Ask Children's

For Family & Patients

I am a...

Quicklinks

Find-A-Provider

Find-A-Location

Services

Health Info

About Us

Research

Your Visit

Search our site:

PBTC 039 - Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery

Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma

Starting Locations:

Legal:

Mobile App:

About Akron Children's